AudioEye Inc.’s (OTCQB: AEYE) share value soared Oct. 6, with 649,578 shares changing hands, significantly higher than its 30-day average volume of 438,103 shares.
The volume is being triggered in part by the Arizona-based voice-activated technology company’s recent Oct. 6 announcement that expects to be profitable for the quarter ended Sept. 30, 2014.
According to AudioEye, it plans to report revenue of $4.7 million for the quarter ending Sept. 30, which is 55% more than its revenue for the quarter ending June. 30.
Strong Financials
Unlike so many penny stocks, AudioEye’s financials have been consistently strong.
Here is a summary of its 10Q, covering the quarter ending June 30:
Cash on hand: $514, 100Current assets: $4.3 million
Current liabilities: $1.3 million
Revenue: $3 million
Net income: $1 million
On Oct. 6, AEYE’s share value closed at 68 cents, up 8 cents, or 14.17% from its closing price of 60 cents previous day.
Find out what could be the best investor’s move when it comes to AEYE by getting the complete report here or by cutting and pasting the following link in your Web browser:
Implant Science’s Security Product Passes European Civil Aviation Conference’s Evaluation
Implant Sciences Corp.’s (OTCQB: IMSC) announced Oct. 6 that its latest sensor product has successfully passed the European Civil Aviation Conference’s evaluation for airport checkpoint screening of passengers and baggage.
The product, known as the TQS-B220, uses Ion Mobility Spectrometry to rapidly detect and identify trace amounts of a wide variety of military, commercial and homemade explosives
This news helped spur Implant Science’s robust stock volume of 369,250 shares traded Oct. 6, which is higher than its 30-day average volume of 335,210 shares.
However, Implant Science’s last 10-Q covering the time period ending Mar. 31 shows that the company is sporting a substantial net loss.
Here is a summary:
Quarterly net loss: $4.9 million
Quarterly revenue: $2.7 million
Cash on hand: $276,000
Current assets: $4.7 million
Current liabilities: $62 millionConsiderable Debt
Also troubling some industry analysts is the fact that Implant Sciences’ staggering liabilities are being funded in part by debt convertible into common stock. They warn that this could lead to a serious dilution issue somewhere down the road.
On Oct. 6, IMSC’s stock value closed at $1.30, up 7 cents from its close of $1.23 the previous day.
Find out what could be the best investor’s move when it comes to IMSC by getting the complete report here or by cutting and pasting the following link in your Web browser:
GeoVax’s Share Value Continues to Soar on Promise to Develop Ebola Vaccine
GeoVax Labs Inc.’s (OTCQB: GOVX) stock value and volume continued their upward trend Oct. 6 on recent news the Atlanta-based bio-tech company is developing an Ebola vaccine.
On Oct. 6, GOVX’s share price closed at 34 cents, up 2 cents, or 6.58% from its closing price of 32 cents the previous day. Its stock volume skyrocketed, with 573,461 shares changing hands, more than 8 times its 30-day average volume of 68,976 shares.
Ebola Vaccine Development
On Oct. 2, GeoVax announced that it has initiated a new program for the development of a safe and effective vaccine to prevent Ebola infection.
With a fast-moving epidemic threatening large populations in Africa, and no proven therapy available, an effective vaccine against Ebola is desperately needed. According to the company, the GeoVax recombinant MVA platform is uniquely suited to deliver a potent and safe vaccine capable of protecting people against Ebola hemorrhagic fever.
GeoVax's Ebola vaccine development efforts will be facilitated by the Company's close proximity to, and collaboration with, the U.S. Centers for Disease Control (CDC) in Atlanta and its experts and Biosafety Level 4) facilities for testing vaccine responses against lethal hemorrhagic viruses.
Since 1976, when Ebola was first discovered, over 20 outbreaks have occurred. Ebola naturally infects animals including bats, creating a reservoir of Ebola that, like rabies, cannot be eradicated completely. An effective vaccine against Ebola would dramatically reduce the epidemic spread of infections as well as the transmission of Ebola from its natural animal hosts to humans.
Find out what could be the best investor’s move when it comes to GOVX by getting the complete report here or by cutting and pasting the following link in your Web browser:
Amarantus BioScience Awaits FDA Review of Recent Clinical Trial
Amarantus BioScience Inc.’s (OTCQB: AMBS) share volume was flat Oct.6, with just 3 million shares changing hands, compared to its 30-day average volume of 9.4 million shares.
The flat volume comes on the heels of news the San Francisco biopharma company that’s developing treatments for such neurodegenerative diseases as Parkinson’s and Alzheimer’s has sent a letter to the FDA.
In the letter, the company is requesting a review and written feedback on the Phase IIb clinical trial design for Eltoprazine in levodopa-induced dyskinesia, a common side effect of levodopa treatment in Parkinson's disease patients.
Amarantus has already been granted worldwide rights to Eltoprazine. This is a new drug that treats Parkinson’s disease and recently went through Phase2 trials during which it was given to 700 patients.
Long Regulatory Process
Perhaps the need for a review is a reminder to Amarantus shareholders just how long and winding the road to final FDA approval is, that is, if it ever comes.
This could be part of the reason why AMBS shares have lost more than half of their value since Jul. 29.
On Oct. 6, AMBS’s share price closed at 9 cents, unchanged from the previous day’s close of 10 cents.
Find out what could be the best investor’s move when it comes to AMBS by getting the complete report here or by cutting and pasting the following link in your Web browser:
ABOUT US:
www.sixfigurestockpicks.com issues momentum alerts on stocks that can provide gains to day traders.
www.sixfigurestockpicks.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
www.sixfigurestockpicks.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals www.pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the www.pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: www.sixfigurestockpicks.com
Disclosure
www.sixfigurestockpicks.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.